News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Somaxon Pharmaceuticals, Inc. (SOMX) Announces Settlement of Silenor Patent Litigation With Mylan Pharmaceuticals, Inc. (MYL) and Par Pharmaceutical Companies, Inc. (PRX)



7/18/2012 9:31:28 AM

SAN DIEGO, July 17, 2012 (GLOBE NEWSWIRE) -- Somaxon Pharmaceuticals, Inc. (Nasdaq:SOMX), a specialty pharmaceutical company, today announced that it has entered into separate settlement arrangements with Mylan Inc. and its subsidiary, Mylan Pharmaceuticals, Inc. and Par Pharmaceutical Companies, Inc. and its subsidiary Par Pharmaceutical, Inc. to resolve pending patent litigation involving SilenorĀ® 3 mg and 6 mg tablets.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES